The Cost of Providing Methadone Maintenance Treatment in Ontario, Canada

REFERENCES

• Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21(2):193–195.
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: Results from the National Treatment Outcome Research Study. AIDS Care 2002; 14(1):77–93.
   PubMed Web of Science ®Google Scholar
• Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90(7):1100–1111.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess 2007; 11(9):1–171, iii–iv.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. DEA, Drug Scheduling, 2008.
   Google Scholar
• European Monitoring Centre for Drugs and Addiction. Cost and Financing of Drug Treatment Services in Europe: An Exploratory Study. Luxembourg: European Monitoring Centre for Drugs and Addiction, 2011.
   Google Scholar
• Moore TJ, Ritter A, Caulkins JP. The costs and consequences of three policy options for reducing heroin dependency. Drug Alcohol Rev 2007; 26(4):369–378.
   PubMed Web of Science ®Google Scholar
• Shanahan M, Havard A, Mills K, Williamson A, Ross J, Teesson M, Darke S, Ali R, Ritter A, Cooke R, Lynskey M. Health Services Use and Treatment Costs Over 12 Months among Heroin Users: Findings from the Australian Treatment Outcome Study (ATOS). Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2003.
   Google Scholar
• Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: Economic evaluation of prison methadone. Drug Alcohol Depend 2006; 84(2):160–166.
   PubMed Web of Science ®Google Scholar
• Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: A cost-effectiveness analysis. Drug Alcohol Depend 2003; 71(3):295–302.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441–452.
   PubMed Web of Science ®Google Scholar
• Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94(4):479–488.
   PubMed Web of Science ®Google Scholar
• Roebuck MC, French MT, McLellan AT. DATStats: Results from 85 studies using the Drug Abuse Treatment Cost Analysis Program. J Subst Abuse Treat 2003; 25(1):51–57.
   PubMed Web of Science ®Google Scholar
• Zarkin GA, Dunlap LJ, Homsi G. The substance abuse services cost analysis program (SASCAP): A new method for estimating drug treatment services cost. Eval Program Plann 2004; 27:35–43.
   Web of Science ®Google Scholar
• Dunlap LJ, Zarkin GA, Cowell AJ. Examining variation in treatment costs: A cost function for outpatient methadone treatment programs. Health Serv Res 2008; 43(3):931–950.
   PubMed Web of Science ®Google Scholar
• French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 1997; 14(5):445–455.
   PubMed Web of Science ®Google Scholar
• Zarkin GA, Dunlap LJ. Implications of managed care for methadone treatment. Findings from five case studies in New York State. J Subst Abuse Treat 1999; 17(1–2):25–35.
   PubMed Web of Science ®Google Scholar
• French MT, Popovici I, Tapsell L. The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. J Subst Abuse Treat 2008; 35(4):462–469.
   PubMed Web of Science ®Google Scholar
• Jones ES, Moore BA, Sindelar JL, O’Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009; 99(1–3):132–140.
   PubMed Web of Science ®Google Scholar
• College of Physicians and Surgeons of Ontario. Methadone Maintenance Guidelines. Toronto: College of Physicians and Surgeons of Ontario, 2005.
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario Ministry of Health and Long-Term Care – Ontario Health Insurance – Schedule of Benefits and Fees for Laboratory Services. Toronto: Queen’s Printer for Ontario, 2009.
   Google Scholar
• College of Physicians and Surgeons of Ontario. Annual Report 2009. Toronto, 2009.
   Google Scholar
• Strike CJ, Gnam W, Urbanoski K, Fischer B, Marsh DC, Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict Behav 2005; 30(5):1025–1028.
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario Ministry of Health and Long-Term Care – Ontario Health Insurance – Schedule of Benefits for Physician Services. Toronto: Queen’s Printer for Ontario, 2010.
   Google Scholar
• Hart WA, Methadone Maintenance Treatment Practices Task Force. Report of the methadone maintenance treatment practices task force, 2007.
   Google Scholar
• College of Physicians and Surgeons of Ontario. Annual Report 2008. Toronto, 2008.
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario Ministry of Health and Long-Term Care – Public Information – Ontario Drug Benefit: Dispensing Fees. Toronto: Queen’s Printer for Ontario, 2002.
   Google Scholar
• OJTBF. Dispensing Fees and Health Benefit Costs. Toronto: OJTBF, 2009, p. Ontario dispensing fees.
   Google Scholar
• Sun Life Assurance Company of Canada. Pay-direct drug plans: Changes to the dispensing fee payments for Ontario pharmacies. Toronto, 2010.
   Google Scholar
• Lewis S. Ontario Generic Drug Wars, Part 3: The Soul of the Pharmacy Profession. In: Essays: Longwoods.Com. Toronto: Longwoods, 2010.
   Google Scholar
• ClaimSecure. Extemporaneous Compound Guidelines. ClaimSecure, 2003.
   Google Scholar
• Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can Med Assoc J 2012; 184(6):E317–E328.
   Web of Science ®Google Scholar
• Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, Krausz M, Anis A, Schechter MT. The North American Opiate Medication Initiative (NAOMI): Profile of participants in North America’s first trial of heroin-assisted treatment. J Urban Health 2008; 85(6):812–825.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Nosyk B, Marsh DC, Guh D, Brissette S, Gartry C, Krausz M, Anis A, Schechter MT. Scientific and political challenges in North America’s first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study. Clin Trials 2009; 6(3):261–271.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance for opioid dependence. Addiction 2001; 96(9):1267–1278.
   PubMed Web of Science ®Google Scholar
• French MT, Roebuck MC, McLellan AT, Sindelar JL. Can the treatment services review be used to estimate the costs of addiction and ancillary services?. J Subst Abuse 2000; 12(4):341–361.
   PubMedGoogle Scholar
• McCollister KE, French MT, Pyne JM, Booth B, Rapp R, Carr C. The cost of treating addiction from the client’s perspective: Results from a multi-modality application of the Client DATCAP. Drug Alcohol Depend 2009; 104(3):241–248.
   PubMed Web of Science ®Google Scholar